Frag' FlorenceEvidenz. Klar. Anwendbar.
Uhr 7/8Sources Journal Tree
Easy Demo

Florence Themenbrowser · Onkologie · Seite 10

Was ist neu im Gesundheitswesen?

Entdecken Sie tatsächlich neu veröffentlichte Arbeiten aus Medizin, Pflege, Therapie, Public Health und Life Sciences. Sortiert nach Publikationsdatum, nicht nach Zitierhäufigkeit.

Themen erkunden

Aktuelle Forschung nach Fachgebiet

23 neue Nachweise auf dieser Seite Publiziert in den letzten 30 Tagen Neueste zuerst Crossref DOI
27.08.2026journal-article

Neuro-Oncology

34 Therapeutic Targeting of the SLC7A11-GCLM-GPX4 Axis Sensitizes Glioblastoma to Ferroptosis and Associates with Poor Survival

Minakshi Behera, Suvendu Purkait, Amit Ghosh, Rabi Narayan Sahu, Sandip Kumar Barik

Abstract Background Glioblastoma (GBM) is the most common malignant primary brain tumor with a dismal prognosis. The high proliferative activity of GBM is prone to generating oxidative stress, which must be counteracted to support cell survival and prevent ferroptotic cell death. Objective The present study evaluated the expression of the GPX-4 and GCLM involved in redox homeostasis in GBM and their possible implications for tumor biology, clinical outcome, and therapeutic potential. Methodology The mRNA and protei …

27.08.2026journal-article

Neuro-Oncology

32 A FLASH of Hope - Preventing Recurrent Glioblastoma

Riddhi Sharma, William Timbury, Sean Gettings, Raymond Shek, Stuart Smith, Ruman Rahman, Nora Bourbia

Abstract Introduction Glioblastoma (GBM) remains the most aggressive and lethal primary brain tumour, with a 5-year survival rate of only ∼13% and a recurrence rate approaching 90% within two years of diagnosis. Current treatment options include surgery followed by radiotherapy and chemotherapy, but these are limited by radioresistance and the inability to eliminate residual infiltrative cells. There is an urgent need for more effective, kinder treatment strategies that prevent recurrence. This project has, so far, …

27.08.2026journal-article

Neuro-Oncology

51 Does it matter where you are treated? Insights from a national review of NHS brain tumour services (2020-2026)

Jill Sokratous, Andrew Wright, Nicky Huskens, Camille Goetz

Abstract Introduction Despite advances in brain tumour care, evidence suggests that patients face variations in treatment, care and research opportunities. To further explore equity of care in the context of the United Kingdom (UK) and identify key challenges, we reviewed NHS brain tumour services. Method We collected data from 25 neuro-oncology centres (covering 90% of the UK population) in 2020–2022 and again in 2024–2026 through the Tessa Jowell Centre of Excellence, a UK-wide benchmarking and service improvemen …

27.08.2026journal-article

Neuro-Oncology

19 Developing a Teenage and Young Adult Brain Tumour Standard Operating Procedure in a UK Tertiary Neurosciences Centre

Aimee Goel, Natalia Koc, Sumbal Nawaz, Andrew Kay

Abstract Introduction Teenage and Young Adult (TYA) patients aged 16–24 years represent a biologically and clinically distinct cohort of central nervous system (CNS) tumour patients. Despite national standards for TYA cancer care, no dedicated management pathway for TYA brain tumours exists at Trust or national level. We developed a Trust-wide Standard Operating Procedure (SOP) for TYA CNS tumours at University Hospitals Birmingham (UHB), alongside an artificial intelligence (AI)-assisted framework for structured S …

27.08.2026journal-article

Neuro-Oncology

36 The cost of a brain tumour: The Economic Case for Urgent Action

Clair Thorstensen-Woll, Marcus Cahill-Evans, Katie Murray, Elana Greaves, Joe Goldbacher, Rob Malcolm, Matthew Taylor

Abstract Introduction Each year over 13,000 people are diagnosed with brain tumours in the UK and 5,400 people lose their lives. Brain tumours have a substantial impact on individual health and on wider society; however, little research has been conducted to estimate the overall burden that brain tumours have on society in the UK. Methods The lifetime burden of illness from brain tumours diagnosed in 2025 was calculated from several sources. There were two categories of impact: (i) financial costs and (ii) health i …

27.08.2026journal-article

Frontiers in Endocrinology

Pre-treatment serum phosphate as a metabolic correlate of live birth after IVF/ICSI: a retrospective cohort study

Zhilong Wang, Xiaoyue Shen, Qingqing Shi, Yuan Yan, Chuanming Liu, Ruiwei Jiang, Feifei Lu, Lingjuan Wang, Jie Mei, Yue Jiang, Weihong Zhou, Na Kong

Background Oocyte developmental competence is influenced by the systemic metabolic milieu during folliculogenesis. Inorganic phosphate is essential for ATP synthesis, nucleic acid metabolism, and phosphorylation-dependent signalling, but its relationship with assisted reproductive technology outcomes remains unclear. We investigated whether pre-treatment fasting serum phosphate was associated with live birth after first IVF/ICSI fresh embryo transfer. Methods This retrospective cohort study included 2, 226 women ag …

27.08.2026journal-article

Cancers

Personalized Oncology: Organizing Cancer Treatment Around Patient Biology

Julianna Lisziewicz, Oliver Wueseke, Franco Lori

Clinical guidelines remain the foundation of evidence-based oncology, translating population-derived evidence into treatment recommendations for defined patient groups. However, patients with rare cancers, complex tumor biology, or treatment-refractory disease may reach a point at which applicable evidence is limited, or guideline-recommended treatment options have been exhausted. We propose Personalized Oncology as a complementary framework for treatment selection in these situations. Rather than asking only which …

27.08.2026journal-article

Neuro-Oncology

108 Interpretable Radiomics-Based Prediction of IDH Status in Glioma

Abdulkerim Duman, James R Powell, Emiliano Spezi

Abstract Introduction Glioblastoma (GBM) is the most frequent primary brain tumour. The 2021 WHO CNS Tumour Classification highlights the importance of IDH mutation status for accurate diagnosis and treatment. However, biopsies are invasive and may not fully capture tumour heterogeneity in GBM. We explored if non-invasive MRI-based radiomic analysis can predict the IDH mutation status of Glioma. Method Utilising the open-access UCSF and a local cohort (STORM_GLIO), a multi-institutional dataset (n = 376, Grade 4) w …

27.08.2026journal-article

Neuro-Oncology

150 The Value of Early Biological Information in Glioblastoma Drug Development: A Health Economic Evaluation of Window-of-Opportunity Trials

Melyda Melyda, Sue Jowett, Peter Auguste, Victoria Wykes, Collin Watts, Gary Middleton, Vinton Cheng

Abstract Introduction Window-of-opportunity (WoO) trials are increasingly proposed in glioblastoma drug development to test early biological activity (tumour penetration and target engagement), before progression to large, costly late-phase trials. While WoO designs may improve early decision-making, they introduce additional operational complexity and upfront costs. Their economic value remains uncertain. Methods An early decision-analytic model was developed to assess the cost-effectiveness of incorporating a WoO …

27.08.2026journal-article

Bioengineering

DTARNU-Net: Dense Tiered Attention Residual Nested U-Net for CT Liver Tumor Segmentation

Kumar P, Robert P, Parthasarathy Ramadass, Mohd Anul Haq

Liver tumor segmentation is a significant task in clinical imaging that involves detecting liver tumors and distinguishing them from the surrounding liver tissue in CT scans. Precision segmentation performs important roles in the initial detection of liver cancer, treatment planning, and monitoring disease development, which also supports doctors, facilitating surgeries and radiation therapy more efficiently. Meanwhile, clinical imaging and segmentation algorithms have been enhanced over the years. The currently pr …

27.08.2026journal-article

Clinical Cancer Research

A Phase 1 First-Time-in-Human, Open-Label Study of Nelistotug Administered to Patients with Advanced Solid Tumors

Lillian L. Siu, Omid Hamid, Reva Schneider, Jordi Rodon. Ahnert, Scott A. Laurie, Frank Stephen. Hodi, Dong-Wan Kim, Myung-Ju Ahn, Gary Carlson, Hussein Assi, Hamza Khan, Patrick Hanafin, Emily Moore, Madhu Ramaswamy, Reza Mozaffari, Stefan Zajic, Arindam Dhar, Ivan Diaz Padilla, Noboru Yamamoto

Abstract Purpose: This first-in-human, nonrandomized, multicenter study investigated nelistotug (anti-CD96 monoclonal antibody [mAb]) as monotherapy (Arm A) and in combination with dostarlimab (anti-PD-1 mAb) (Arm B), and dostarlimab plus belrestotug (anti-TIGIT mAb) (Arm F) in patients with recurrent or advanced solid tumors. Patients and Methods: Patients received intravenous doses every 3 weeks of nelistotug 2.1–1400 mg, nelistotug 70–1400 mg plus dostarlimab 500 mg, or nelistotug 1400 mg plus dostarlimab 500 mg …

27.08.2026journal-article

Cancer Research

Phase Separation of ZBED2 Stabilizes ILK to Drive Metastasis and Immune Evasion in Esophageal Squamous Cell Carcinoma

Taoyang Xu, Xueping Luo, Mao Lin, Jiao-Jiao Xu, Li Qiu, Huining Liu, Qier Mu, Tong Yang, Jiaxi Chen, Wangcheng He, Siyuan Ma, Shengyuan Jiang, Jing Yang, Yan He, Can-Can Zheng, Xingyang Xue, Xin Hao, Lian Zhang, Jun Liu, Bin Li, Wenwen Xu

Abstract Metastasis remains a leading cause of mortality in patients with esophageal squamous cell carcinoma (ESCC), underscoring the urgent need to elucidate the molecular mechanisms driving disease progression. In this study, we delineated that zinc finger BED-type containing 2 (ZBED2), a zinc finger protein, correlates with inferior survival outcomes and metastasis in patients with ESCC. ZBED2 formed phase-separated nuclear condensates that functionally promote tumor metastasis, and integrin-linked kinase (ILK) …

27.08.2026journal-article

BMC Women's Health

Long-term risk of second primary malignancies and symptomatic heart failure after pegylated liposomal doxorubicin versus conventional anthracycline-based chemotherapy in early-stage breast cancer survivors: a single-center experience

Yu-Ting Lee, Hsin-Yi Yang, Chi-Wen Tu, Yu-Chen Hsu, Min-Chieh Shieh, Cheng-Yen Lee, Chih-Chia Chang, Yuk-Wah Tsang, Yu-Wen Wang, Wei-Yu Wang, Chin-Ho Kuo, Ming-Yang Lee, Yin-Che Lu, Po-Yen Hsu, Michael W. Y. Chan

Abstract Background Anthracycline-based chemotherapy is a crucial treatment for early-stage breast cancer but be associated with second primary malignancy (SPM) and heart failure (HF). Pegylated liposomal doxorubicin (PLD) has been used as an alternative to conventional non-pegylated anthracyclines; however, long-term data regarding SPM and symptomatic HF after PLD-based treatment remain limited. This study evaluated the long-term risks of SPM and symptomatic HF and compared survival outcomes between PLD-based and …

27.08.2026journal-article

Frontiers in Endocrinology

Case Report: Pasireotide treatment in neonatal congenital hyperinsulinism due to a homozygous ABCC8 mutation

Calvin Kurz, Marcia Roeper, Lisa Friesl, Ertan Mayatepek, Thomas Meissner, Sebastian Kummer, Henrike Hoermann, Alena Welters

Mutations in ABCC8 and KCNJ11 are associated with the most severe and diazoxide-resistant forms of congenital hyperinsulinism (CHI). Somatostatin analogues are commonly used off-label as second-line treatment. While octreotide and lanreotide are the most established options, pasireotide—a second-generation somatostatin analogue with higher affinity for somatostatin receptor subtype 5—has been hypothesized to offer improved suppression of insulin secretion. We report the off-label use of subcutaneous pasireotide in …

27.08.2026journal-article

Journal of Oncology Pharmacy Practice

Pharmaceutical care in patients with gastric cancer treated with capecitabine: A randomized clinical trial

Patrícia Kaiser Pedroso Cava, Camille Nigri Cursino, Larissa Dos Santos Sebould Marinho, Ana Clara Duarte Dos Santos, Ariela Dutra Norberto De Oliveira, Larissa Rodrigues Nascimento, Vanessa Cristiane Da Silva Ferreira, Dulce Helena Nunes Couto, Jessica Pronestino De Lima Moreira, Thaísa Amorim Nogueira, Selma Rodrigues De Castilho, Sabrina Calil-Elias

Introduction Cancer poses a major challenge to global health, impacting individuals, communities and societies worldwide. A significant proportion of global morbidity and mortality from neoplasms is accounted for by gastrointestinal tumors, due to their high incidence and lethality. Capecitabine, an oral antineoplastic agent, has brought advances in treatment, but requires caution regarding adherence and adverse events. In this context, it is believed that pharmaceutical care can significantly contribute to optimiz …

27.08.2026journal-article

PLOS One

Expedited pathway portfolios, trial complexity, and FDA approval timelines in oncology and neurology: A comparative analysis

Ahmed M. Sayed, Nada M. Ezzelarab, Nguyen Tien Huy

FDA expedited programs are intended to facilitate development and review for therapies addressing serious conditions with unmet medical need, but their use may depend on whether the evidentiary package is compatible with regulatory acceleration. We compared FDA original approvals in oncology and neurology from 2015 to 2024 to evaluate whether differences in approval timing reflected expedited pathway portfolio intensity, pivotal evidence architecture, or alignment between the two. We conducted a retrospective compa …

27.08.2026journal-article

International Journal of Clinical Oncology

Proteinuria as the cause of early dose modification in Japanese patients with metastatic colorectal cancer treated with fruquintinib: a multicenter real-world study

Shohei Udagawa, Chihiro Ishizuka, Hiroki Osumi, Toshiharu Hirose, Natsuko Okita, Hidekazu Hirano, Hirokazu Shoji, Ken Kato, Koichiro Yoshino, Keitaro Shimozaki, Shota Fukuoka, Takeru Wakatsuki, Mariko Ogura, Akira Ooki, Keisho Chin, Kensei Yamaguchi, Atsuo Takashima, Eiji Shinozaki

Abstract Background Fruquintinib has demonstrated survival benefits in patients with previously treated metastatic colorectal cancer (mCRC) in phase III trials. However, real-world data in Japanese patients remain limited. This study evaluated the effectiveness and safety of fruquintinib in routine clinical practice. Methods We conducted a retrospective observational study at two cancer centers. Patients treated with fruquintinib for mCRC between November 2024 and December 2025 were included. Clinical outcomes and …

27.08.2026journal-article

Philosophical Transactions of the Royal Society B: Biological Sciences

Looking back on the history of epidermal growth factor receptor mutations in lung cancer

Roy S. Herbst, Meina Wang, Katerina Politi

Abstract The discovery of the epidermal growth factor receptor (EGFR) represents a landmark achievement in biomedical science, laying the foundation for one of the most transformative success stories in oncology. From the early isolation of epidermal growth factor (EGF) by Stanley Cohen and colleagues to the cloning of EGFR and its identification as a receptor tyrosine kinase, these pioneering studies revealed its central role in cellular growth and proliferation and ultimately linked EGFR signalling to cancer. Ear …

27.08.2026journal-article

International Journal of Cancer

The Africa We Want : A Perspective on the African Code Against Cancer To Be Developed for Sub‐Saharan Africa

Anthony Kityo, Phyllis Ohene‐Agyei, Felix M. Onyije, Hannah Simba, Annet Nakaganda, Denis Chopera, Kofi Mensah Nyarko, Benido Impouma, Mary Nyangasi, Blandina Mmbaga, Valerie McCormack, Cesaltina Lorenzoni, Miriam Mutebi, Joachim Schüz, Carolina Espina

ABSTRACT Sub‐Saharan Africa (SSA) faces a unique cancer burden, characterized by a disproportionately high mortality‐to‐incidence ratio, a large share of infection‐related cancers, and distinct environmental exposures. Implementation of national policies on primary prevention is limited, and public literacy regarding cancer risk and curability remains low. Furthermore, the implementation of existing prevention and treatment interventions is hindered by resource constraints and deeply rooted cultural beliefs. Thus, …

27.08.2026journal-article

Journal of Microbiology & Biology Education

An innovative course-based undergraduate research experience (CURE) in HPV-associated cervical cancer: integrating molecular oncology research and scientific writing in undergraduate education

Sadaf Khursheed Baba, Tooba Jawwad, Asma Al Menhali, Sameer Mirza

ABSTRACT Course-based undergraduate research experiences (CUREs) widen access to authentic research by embedding open-ended investigations into undergraduate curricula. Here, we describe a semester-long CURE in cancer biology that integrates molecular biology techniques, data analysis, and structured scientific writing within an upper-level undergraduate course. Students engaged in the study of HPV-associated cervical carcinogenesis by investigating the role of a candidate gene using siRNA-mediated knockdown and qu …

27.08.2026journal-article

Razi Medical Journal

Efficacy of Methotrexate Treatment in Women with Tubal Ectopic Pregnancy, University Hospital, Tripoli, Libya

Noura Elawam

The use of methotrexate for the treatment of women with tubal ectopic pregnancies is now common practice. However, the clinical and hormonal determinants of the success of this treatment are not known. Methods: We studied 120 women with tubal ectopic pregnancies who were treated with methotrexate intramuscularly according to a single-dose protocol. Pretreatment serum concentrations of human chorionic gonadotropin and progesterone, the size and volume of the gestational mass, fetal cardiac activity, and the presence …

27.08.2026journal-article

Neuro-Oncology

94 Outcome of patients with metastatic lung cancer presenting with synchronous brain metastases – A single centre; 5 year retrospective analysis

Harriet Hebbes, Sara Walters, Patrick Forster, Jillian Maclean, James Powell, Sahar Iqbal

Abstract Introduction Metastatic non-small cell lung cancer (NSCLC) with synchronous brain metastases (BM) impacts prognosis and therapeutic considerations. Up to 20% patients with NSCLC may develop BM. Clinical trials of whole brain radiotherapy (WBRT), neurosurgical resection and stereotactic radiosurgery outdate the recent advances in systemic therapy for NSCLC. Methods Retrospective data was collected on all patients with NSCLC who presented with synchronous BM between 2017-2022. This included demographics, his …

27.08.2026journal-article

Neuro-Oncology

39 Barriers to participation in research: the experience of people with brain tumours

Clair Thorstensen-Woll, Marcus Cahill-Evans

Abstract Introduction Brain tumours remain the biggest cancer killer of people under 40, with minimal survival improvements over recent decades. Despite the critical role of research in advancing understanding, improving treatments and ultimately, patient outcomes, many people diagnosed with brain tumours experience significant barriers to participating in research activities such as clinical trials or tissue donation. This report explores the systemic and patient-centred barriers that hinder research participation …